Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature

Ilaria Marech, Angelo Vacca, Antonio Gnoni, Nicola Silvestris, Vito Lorusso

Research output: Contribution to journalArticlepeer-review

Abstract

Gefitinib is the current first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutations. The possibility of using gefitinib as neoadjuvant therapy is interesting because of the low toxicity profile of tyrosine kinase inhibitors. Here we report the case of a 67-year-old nonsmoking woman affected by locally advanced lung adenocarcinoma, in whom one-year treatment with gefitinib rendered the tumor amenable to surgical removal. The results of ongoing clinical trials exploring the ability of preoperative gefitinib to achieve better results than can be obtained with chemotherapy in patients selected on the basis of EGFR mutations are urgently awaited.

Original languageEnglish
JournalTumori
Volume99
Issue number5
DOIs
Publication statusPublished - Sep 2013

Keywords

  • EGFR gene mutation
  • Gefitinib
  • Neoadjuvant therapy
  • NSCLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature'. Together they form a unique fingerprint.

Cite this